TY - JOUR
T1 - Precision medicine in neuroendocrine neoplasms
T2 - An update on current management and future perspectives
AU - Gaudenzi, Germano
AU - Dicitore, Alessandra
AU - Carra, Silvia
AU - Saronni, Davide
AU - Pozza, Carlotta
AU - Giannetta, Elisa
AU - Persani, Luca
AU - Vitale, Giovanni
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Neuroendocrine neoplasms (NENs) are traditionally considered as a single group of rare malignancies that originate from the highly spread neuroendocrine system. The clinical management is complex due to the high heterogeneity of these neoplasms in terms of clinical aggressiveness and response to the therapy. Indeed, a multidisciplinary approach is required to reach a personalization of the therapy, including cancer rehabilitation. In this review, we discuss the possibility to adopt a precision medicine (PM) approach in the management of NENs. To this purpose, we summarize current knowledge and future perspectives about biomarkers and preclinical in vitro and in vivo platforms, potentially useful to inform clinicians about the prognosis and for tailoring therapy in patients with NENs. This approach may represent a breakthrough in the therapy and tertiary prevention of these tumors.
AB - Neuroendocrine neoplasms (NENs) are traditionally considered as a single group of rare malignancies that originate from the highly spread neuroendocrine system. The clinical management is complex due to the high heterogeneity of these neoplasms in terms of clinical aggressiveness and response to the therapy. Indeed, a multidisciplinary approach is required to reach a personalization of the therapy, including cancer rehabilitation. In this review, we discuss the possibility to adopt a precision medicine (PM) approach in the management of NENs. To this purpose, we summarize current knowledge and future perspectives about biomarkers and preclinical in vitro and in vivo platforms, potentially useful to inform clinicians about the prognosis and for tailoring therapy in patients with NENs. This approach may represent a breakthrough in the therapy and tertiary prevention of these tumors.
UR - http://www.scopus.com/inward/record.url?scp=85068693723&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068693723&partnerID=8YFLogxK
U2 - 10.1530/EJE-19-0021
DO - 10.1530/EJE-19-0021
M3 - Review article
C2 - 31048562
AN - SCOPUS:85068693723
VL - 181
SP - R1-R10
JO - European Journal of Endocrinology
JF - European Journal of Endocrinology
SN - 0804-4643
IS - 1
ER -